Zacks: Brokerages Anticipate Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Will Post Earnings of $0.28 Per Share

Wall Street analysts expect Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) to announce $0.28 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Harmony Biosciences’ earnings, with estimates ranging from $0.22 to $0.33. Harmony Biosciences reported earnings per share of ($0.14) in the same quarter last year, which would suggest a positive year-over-year growth rate of 300%. The company is scheduled to announce its next quarterly earnings report on Thursday, November 11th.

On average, analysts expect that Harmony Biosciences will report full year earnings of $1.04 per share for the current year, with EPS estimates ranging from $0.89 to $1.19. For the next fiscal year, analysts anticipate that the firm will report earnings of $2.54 per share, with EPS estimates ranging from $1.95 to $3.12. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Harmony Biosciences.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Monday, August 9th. The company reported $0.24 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.18 by $0.06. Harmony Biosciences had a net margin of 9.86% and a return on equity of 66.92%. The company had revenue of $73.82 million for the quarter, compared to analyst estimates of $70.85 million.

Separately, Zacks Investment Research upgraded shares of Harmony Biosciences from a “hold” rating to a “buy” rating and set a $30.00 price target for the company in a report on Wednesday, August 11th.

In related news, insider Jeffrey M. Dayno sold 9,950 shares of the business’s stock in a transaction that occurred on Tuesday, August 10th. The stock was sold at an average price of $30.21, for a total transaction of $300,589.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John C. Jacobs sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, September 13th. The stock was sold at an average price of $35.93, for a total value of $898,250.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 42,159 shares of company stock valued at $1,460,926. Corporate insiders own 28.80% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC increased its stake in Harmony Biosciences by 5.4% during the first quarter. Janus Henderson Group PLC now owns 1,153,783 shares of the company’s stock worth $38,120,000 after acquiring an additional 59,334 shares during the last quarter. Nuveen Asset Management LLC raised its stake in shares of Harmony Biosciences by 449.0% in the 1st quarter. Nuveen Asset Management LLC now owns 55,764 shares of the company’s stock valued at $1,842,000 after acquiring an additional 45,607 shares during the period. Polaris Capital Management LLC acquired a new position in shares of Harmony Biosciences in the 2nd quarter worth approximately $872,000. Virtus ETF Advisers LLC boosted its position in shares of Harmony Biosciences by 2.8% during the 1st quarter. Virtus ETF Advisers LLC now owns 15,322 shares of the company’s stock worth $506,000 after purchasing an additional 423 shares during the period. Finally, Morgan Stanley increased its holdings in Harmony Biosciences by 205.9% in the 1st quarter. Morgan Stanley now owns 63,827 shares of the company’s stock valued at $2,109,000 after purchasing an additional 42,961 shares during the last quarter. 47.65% of the stock is currently owned by institutional investors.

HRMY stock opened at $35.61 on Wednesday. Harmony Biosciences has a 1-year low of $25.09 and a 1-year high of $52.74. The business has a 50-day moving average price of $31.17 and a 200 day moving average price of $30.67. The company has a market capitalization of $2.03 billion and a P/E ratio of 154.83. The company has a debt-to-equity ratio of 1.55, a current ratio of 5.59 and a quick ratio of 5.46.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States.

See Also: What Are Cryptocurrencies?

Get a free copy of the Zacks research report on Harmony Biosciences (HRMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Harmony Biosciences (NASDAQ:HRMY)

Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.